Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more
Market Cap & Net Worth: Xvivo Perfusion AB (publ) (XVIPF)
Xvivo Perfusion AB (publ) (PINK:XVIPF) has a market capitalization of $834.74 Million ($834.74 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #9340 globally and #4510 in its home market, demonstrating a -20.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xvivo Perfusion AB (publ)'s stock price $26.50 by its total outstanding shares 31499470 (31.50 Million).
Xvivo Perfusion AB (publ) Market Cap History: 2015 to 2025
Xvivo Perfusion AB (publ)'s market capitalization history from 2015 to 2025. Data shows growth from $190.57 Million to $834.74 Million (16.84% CAGR).
Xvivo Perfusion AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xvivo Perfusion AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.03x
Xvivo Perfusion AB (publ)'s market cap is 1.03 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
33.26x
Xvivo Perfusion AB (publ)'s market cap is 33.26 times its annual earnings
1.97x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $312.47 Million | $138.18 Million | $1.50 Million | 2.26x | 208.18x |
| 2017 | $353.74 Million | $148.34 Million | $6.26 Million | 2.38x | 56.51x |
| 2018 | $453.59 Million | $187.87 Million | $12.69 Million | 2.41x | 35.76x |
| 2019 | $538.64 Million | $220.84 Million | $4.94 Million | 2.44x | 109.06x |
| 2020 | $881.99 Million | $179.86 Million | -$43.73 Million | 4.90x | N/A |
| 2021 | $975.54 Million | $258.39 Million | $8.15 Million | 3.78x | 119.67x |
| 2022 | $647.31 Million | $415.29 Million | $18.43 Million | 1.56x | 35.13x |
| 2023 | $718.19 Million | $597.54 Million | $91.82 Million | 1.20x | 7.82x |
| 2024 | $1.35 Billion | $822.41 Million | $172.18 Million | 1.64x | 7.85x |
| 2025 | $834.74 Million | $810.13 Million | $25.10 Million | 1.03x | 33.26x |
Competitor Companies of XVIPF by Market Capitalization
Companies near Xvivo Perfusion AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Xvivo Perfusion AB (publ) by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #169 globally with a market cap of $112.92 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #191 globally with a market cap of $103.18 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #169 | Medtronic PLC | NYSE:MDT | $112.92 Billion | $88.24 |
| #191 | Boston Scientific Corp | NYSE:BSX | $103.18 Billion | $69.79 |
Xvivo Perfusion AB (publ) Historical Marketcap From 2015 to 2025
Between 2015 and today, Xvivo Perfusion AB (publ)'s market cap moved from $190.57 Million to $ 834.74 Million, with a yearly change of 16.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $834.74 Million | -38.23% |
| 2024 | $1.35 Billion | +88.16% |
| 2023 | $718.19 Million | +10.95% |
| 2022 | $647.31 Million | -33.65% |
| 2021 | $975.54 Million | +10.61% |
| 2020 | $881.99 Million | +63.74% |
| 2019 | $538.64 Million | +18.75% |
| 2018 | $453.59 Million | +28.23% |
| 2017 | $353.74 Million | +13.21% |
| 2016 | $312.47 Million | +63.97% |
| 2015 | $190.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Xvivo Perfusion AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $834.74 Million USD |
| MoneyControl | $834.74 Million USD |
| MarketWatch | $834.74 Million USD |
| marketcap.company | $834.74 Million USD |
| Reuters | $834.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.